11 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 11 of 11 clinical reviews.
A guide to how Saxenda (liraglutide 3 mg) affects growth, bone density, puberty, and long-term development in adolescents aged 12-17, with trial data, dosing guidance, and safety monitoring protocols.
A guide to using Saxenda (liraglutide 3 mg) safely in adults aged 65 and older, covering exercise adaptations, fall risk, sarcopenia, hypoglycemia caution, and practical daily activity planning.
A guide to liraglutide 3 mg in adolescents aged 12 to 17, covering FDA-approved indications, off-label applications, dosing, efficacy data, and safety considerations.
A guide on starting, adjusting, and transitioning older adults (65+) from pediatric or young-adult obesity care to liraglutide 3 mg (Saxenda) therapy, with dosing tables, safety data, and evidence-based monitoring protocols.
A comprehensive clinical review of Saxenda (liraglutide 3 mg) use in geriatric patients aged 65+, covering efficacy, safety, muscle and bone considerations, dosing, and monitoring guidance backed by primary-source evidence.
Evidence-based guidance on managing Saxenda (liraglutide 3 mg) in pediatric patients under 12, covering school accommodations, physical activity, nausea timing, hypoglycemia protocols, and communication with teachers and coaches.
A clinical review of off-label Saxenda (liraglutide 3 mg) use in children under age 12, covering the regulatory status, available trial data, dosing considerations, and safety signals that clinicians and families should understand.
A guide covering how Saxenda (liraglutide 3 mg) affects school performance, physical activity, lunch routines, sports participation, and daily scheduling for adolescents aged 12 to 17.
Saxenda (liraglutide 3 mg) is not FDA-approved for children under 12. This guide explains the current evidence, regulatory status, off-label considerations, and safe injection technique so caregivers can have informed conversations with their child's prescribing physician.
Complete clinical guide for caregivers administering Saxenda (liraglutide 3 mg) to adults aged 65 and older: injection technique, dose escalation, safety monitoring, and geriatric-specific considerations backed by primary-source evidence.
A clinical review of liraglutide 3 mg (Saxenda) use in children under 12, covering FDA approval status, developmental safety data, growth effects, neurodevelopmental considerations, and what current guidelines recommend.